Plasma Concentration of Suppressor of Tumorigenicity 2 (ST2), the IL33 Receptor, at Initiation of Graft Versus Host Disease Therapy Predicts Day 28 Response and Day 180 Survival Post-Treatment
Year: 2012
Type: article
Abstract: Acute graft-versus-host disease (GVHD) is the primary limitation of allogeneic hematopoietic cell transplantation. Current diagnostic tests do not predict a patient's response to therapy, particularly at GVHD onset, when risk-stratification is most beneficial. We hypothesized that biomarkers discovered using a previously described intact proteomic analysis system (IPAS) approach (Paczesny et al. 2010) will discriminate between therapy responsive (resolution or improvement of GVHD by day (D) 28 post-therapy initiation) and unresponsive (absence of complete or partial response) patients.
Institutions: University of Michigan, Fred Hutch Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W1981943650